Morgan Stanley Acer Therapeutics Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.57 - $1.28 $421 - $947	-740 Reduced 99.87%	1 $0
Q2 2023 Aug 14, 2023	SELL	$0.75 - $1.14 $1,185 - $1,802	-1,581 Reduced 68.09%	741 $0
Q1 2023 May 15, 2023	BUY	$0.67 - $3.05 $89 - $408	134 Added 6.12%	2,322 $1,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $4.15 $15 - $58	14 Added 0.64%	2,188 $5,000
Q3 2022 Nov 14, 2022	SELL	$1.28 - $1.6 $1 - $1	-1 Reduced 0.05%	2,174 $3,000
Q2 2022 Oct 27, 2022	BUY	$1.19 - $3.04 $2,578 - $6,587	2,167 Added 27087.5%	2,175 $3,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $3.04 $2,578 - $6,587	2,167 Added 27087.5%	2,175 $3,000
Q1 2022 Oct 27, 2022	SELL	$1.98 - $2.98 $4,290 - $6,457	-2,167 Reduced 99.63%	8 $0
Q1 2022 May 13, 2022	BUY	$1.98 - $2.98 $13 - $20	7 Added 700.0%	8 $0
Q3 2021 Nov 15, 2021	BUY	$2.3 - $2.86 $2 - $2	1 New	1 $0

365

Ticker ACER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,100,000
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.